Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.
Kaoru FujikawaTakuro SaitoKoji KuroseTakashi KojimaTakeru FunakoshiEiichi SatoKazuhiko KakimiShinsuke IidaYuichiro DokiMikio OkaRyuzo UedaHisashi WadaPublished in: PloS one (2023)
A durable clinical response was noted in some patients, and high lymphocyte levels before treatment initiation may be a biomarker for the efficacy of KW-0761. The synergistic effect of KW-0761 for depleting Tregs and other immunotherapies is expected in the future.